Zhejiang Huahai Pharmaceutical (600521) Q2 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 was RMB 4.52 billion, down 11.93% year-over-year; net profit attributable to shareholders was RMB 409 million, down 45.30%.

• Decline in profit driven by intensified competition, price drops in APIs, increased R&D investment, and reduced forex gains.

• R&D investment rose 23.07% year-over-year, accounting for 14.36% of revenue.

• The company accelerated its transformation towards innovative and biological drugs, with several clinical milestones achieved.

Financial highlights

• Operating income: RMB 4.52 billion, down 11.93% year-over-year.

• Net profit attributable to shareholders: RMB 409 million, down 45.30% year-over-year.

• Operating cash flow: RMB 370 million, down 71.52% year-over-year.

• Basic and diluted EPS: RMB 0.28, down 46.15% year-over-year.

• Gross margin and net margin declined due to price pressure and higher R&D costs.

Outlook and guidance

• The company continues to focus on global market expansion, product pipeline diversification, and innovation-driven growth.

• R&D and new product launches are expected to be key drivers for future growth.

• Management highlights ongoing risks from price competition, regulatory changes, and global trade uncertainties.